Rationale and design of a phase III safety trial of idarucizumab in children receiving dabigatran etexilate for venous thromboembolism

Manuela Albisetti, Arno Schlosser, Martina Brueckmann, Savion Gropper, Stephan Glund, Igor Tartakovsky, Leonardo R Brandão, Paul A Reilly, Manuela Albisetti, Arno Schlosser, Martina Brueckmann, Savion Gropper, Stephan Glund, Igor Tartakovsky, Leonardo R Brandão, Paul A Reilly

Abstract

Background: The incidence of venous thromboembolism (VTE) in children has been increasing. Anticoagulants are the mainstay of treatment but are associated with bleeding events that may be life-threatening. Idarucizumab is a fragment antigen-binding (fab) that provides immediate, complete, and sustained reversal of dabigatran's anticoagulant effects in adults.

Objective and methods: This phase III, open-label, single-arm, multicenter, multinational trial will assess the safety of idarucizumab in children participating in two ongoing trials investigating dabigatran etexilate. Eligible patients will be children with VTE (aged 0-≤18 years; n = ~5) with life-threatening or uncontrolled bleeding (group A), and children who require emergency surgery/urgent procedures for a condition other than bleeding (group B). Patients will receive idarucizumab up to 5 g as two consecutive intravenous infusions over 5-10 minutes each, as two 10-15-minute drips or as two bolus injections (15 minutes apart) and will be monitored for 30 days. The primary endpoint will be the safety of idarucizumab assessed by the occurrence of drug-related adverse events (including immune reactions) and all-cause mortality. Secondary endpoints will be the reversal of dabigatran anticoagulant effects assessed by changes in diluted thrombin time and ecarin clotting time, time to achieve complete reversal and the duration of the reversal and bleeding severity (group A). The formation of antidrug antibodies at 30 days post-dose and cessation of bleeding will also be assessed.

Conclusion: This study will report the safety of idarucizumab in children with VTE who require rapid reversal of the anticoagulant effects of dabigatran. Clinical trial registration: NCT02815670.

Keywords: children; dabigatran etexilate; idarucizumab; oral anticoagulants; venous thromboembolism.

Figures

Figure 1
Figure 1
Trial administrative and oversight structure. aLocal laboratories may be employed, after consultation with the sponsor, to evaluate some assays, such as dTT, for the evaluation of dabigatran activity, international normalized ratio, serum creatinine, and hemoglobin. CRO, Contract Research Organization; DMC, Data Monitoring Committee; dTT, diluted thrombin time; OPU, local Boehringer Ingelheim operating unit; PD, pharmacodynamics; PK, pharmacokinetics; SOP, standard operating procedure; TCM, Trial Clinical Monitor; TMM, Team Member Medicine

References

    1. Raffini L, Huang YS, Witmer C, Feudtner C. Dramatic increase in venous thromboembolism in children's hospitals in the United States from 2001 to 2007. Pediatrics. 2009;124:1001–8.
    1. Kerlin BA. Current and future management of pediatric venous thromboembolism. Am J Hematol. 2012;87(Suppl 1):S68–74.
    1. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta‐analysis of randomised trials. Lancet. 2014;383:955–62.
    1. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.
    1. Connolly SJ, Wallentin L, Ezekowitz MD, et al. The Long‐Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY‐ABLE) Study. Circulation. 2013;128:237–43.
    1. Feuring M, van RJ. The discovery of dabigatran etexilate for the treatment of venous thrombosis. Expert Opin Drug Discov 2016;11:717–31.
    1. Franchini M, Lippi G. Prothrombin complex concentrates: an update. Blood Transfus. 2010;8:149–54.
    1. Lee GM, Welsby IJ, Phillips‐Bute B, Ortel TL, Arepally GM. High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass. Blood. 2013;121:2828–35.
    1. Suarez CJ, Gayoso DP, Gude SF, Gomez Zincke JM, Rey AH, Fontanillo Fontanillo MM. Method to calculate the protamine dose necessary for reversal of heparin as a function of activated clotting time in patients undergoing cardiac surgery. J Extra Corpor Technol. 2013;45:235–41.
    1. Turpie AG, Kreutz R, Llau J, Norrving B, Haas S. Management consensus guidance for the use of rivaroxaban–an oral, direct factor Xa inhibitor. Thromb Haemost. 2012;108:876–86.
    1. Vigue B. Bench‐to‐bedside review: optimising emergency reversal of vitamin K antagonists in severe haemorrhage ‐ from theory to practice. Crit Care. 2009;13:209.
    1. Grottke O, Aisenberg J, Bernstein R, et al. Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran‐induced anticoagulation. Crit Care. 2016;20:115.
    1. Glund S, Moschetti V, Norris S, et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost. 2015;113:943–51.
    1. Glund S, Stangier J, Schmohl M, et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo‐controlled, double‐blind phase 1 trial. Lancet. 2015;386:680–90.
    1. Summary of product characteristics, Praxbind. [cited 2017 July 3]. Available from ema europa eu/docs/en_GB/document_library/EPAR_‐_Product_Information/human/003986/WC500197462 pdf. .
    1. Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373:511–20.
    1. Pollack CV, Reilly PA, van Ryn J , et al. Idarucizumab for dabigatran reversal: updated results of the RE‐VERSE AD study. Circulation. 2016;134(Suppl 1): E714–E715.
    1. ICH Harmonised Tripartite Guideline . Guideline for Good Clinical Practice E6. [cited 2017 February 20]. Available form _Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf.
    1. World Medical Association Declaration of Helsinki . Ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–4.
    1. Mitchell LG, Goldenberg NA, Male C, Kenet G, Monagle P, Nowak‐Gottl U. Definition of clinical efficacy and safety outcomes for clinical trials in deep venous thrombosis and pulmonary embolism in children. J Thromb Haemost. 2011;9:1856–8.
    1. Pradaxa, European Medicines Agency (EMA) . EMA Web site. [cited 2016 Aug 19]. Available form .
    1. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342–52.
    1. Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368:709–18.
    1. Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129:764–72.
    1. Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131:157–64.
    1. Levy JH, Ageno W, Chan NC, Crowther M, Verhamme P, Weitz JI. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14:623–7.
    1. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.
    1. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.
    1. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104.
    1. Young G, Kubitza D, Kenet G, et al. Development of a rivaroxaban dosing regimen for treatment of VTE in children aged 12 to 18 years. J Thromb Haemost. 2017;13(Suppl. 2):1–997.
    1. Boehringer Ingelheim . Safety and tolerability of dabigatran etexilate in adolescents. [cited 2017 June 16]. Available from ; Bethesda, MD:National Library of Medicine (US) 2000 NLMIdentifier: NCT00844415. .
    1. Nowak‐Gottl U, Bidlingmaier C, Krumpel A, Gottl L, Kenet G. Pharmacokinetics, efficacy, and safety of LMWHs in venous thrombosis and stroke in neonates, infants and children. Br J Pharmacol. 2008;153:1120–7.
    1. Chan AK, Monagle P. Updates in thrombosis in pediatrics: where are we after 20 years? Hematology Am Soc Hematol Educ Program. 2012;2012:439–43.
    1. Kuhle S, Eulmesekian P, Kavanagh B, Massicotte P, Vegh P, Mitchell LG. A clinically significant incidence of bleeding in critically ill children receiving therapeutic doses of unfractionated heparin: a prospective cohort study. Haematologica. 2007;92:244–7.
    1. Trucco M, Lehmann CU, Mollenkopf N, Streiff MB, Takemoto CM. Retrospective cohort study comparing activated partial thromboplastin time versus anti‐factor Xa activity nomograms for therapeutic unfractionated heparin monitoring in pediatrics. J Thromb Haemost. 2015;13:788–94.
    1. Rahmat NA, Lip GY. Monitoring the effects and antidotes of the non‐vitamin K oral anticoagulants. Arrhythm Electrophysiol Rev. 2015;4:90–5.
    1. Monagle P, Chan AK, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence‐Based Clinical Practice Guidelines. Chest. 2012;141:e737S–801S.
    1. PRAXBIND prescribing information . 2015.
    1. Schmohl M, Glund S, Harada A, et al. Idarucizumab does not have procoagulant effects: assessment of thrombosis biomarkers in healthy volunteers. Thromb Haemost 2017;117:269–76.
    1. Glund S, Stangier J, van Ryn J, et al. Effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab‐mediated reversal of dabigatran anticoagulant activity in a randomized, double‐blind, crossover phase Ib study. Clin Pharmacokinet. 2017;56:41–54.
    1. Kermer P, Eschenfelder CC, Diener HC, et al. Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany–A national case collection. Int J Stroke. 2017;12:383–91.
    1. Peacock WF, Rafique Z, Singer AJ. Direct‐acting oral anticoagulants: practical considerations for emergency medicine physicians. Emerg Med Int. 2016;2016:1781684.
    1. Shapiro S, Bhatnagar N, Khan A, Beavis J, Keeling D. Idarucizumab for dabigatran overdose in a child. Br J Haematol. 2016. [Epub ahead of print]. 10.1111/bjh.14371.
    1. Sethu S, Govindappa K, Alhaidari M, Pirmohamed M, Park K, Sathish J. Immunogenicity to biologics: mechanisms, prediction and reduction. Arch Immunol Ther Exp (Warsz). 2012;60:331–44.
    1. Norris S, Ramael S, Ikushima I, et al. Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies. Br J Clin Pharmacol. 2017;83:1815–25.
    1. US Department of Health and Human Services, Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) . Guidance for industry: immunogenicity assessment for therapeutic protein products. [cited 2015 June 23]. Available from .

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner